Cell-free system blood plasma or blood serum manufacturing method
Ultrasonic disruption and cell removal techniques enhance the production of cell-free plasma or serum enriched with VEGF or IGF1 by addressing filter clogging and maintaining factor concentration, improving operational efficiency and purity.
Patent Information
- Application Number
- JP2023177310
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-10-13
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-05-26
AI Technical Summary
Existing methods for producing cell-free plasma or serum enriched with VEGF or IGF1 face challenges such as inefficient concentration of these growth factors, filter clogging during processing, and the need for additives, which complicates the production process and reduces factor concentration.
A method involving ultrasonic disruption treatment of plasma or serum at an output of 5W to 500W, followed by removing cells to produce cell-free plasma or serum enriched with VEGF or IGF1, using techniques like centrifugation and filtration with specific pore sizes to avoid clogging and maintain factor concentration.
The method effectively concentrates VEGF and IGF1 without clogging filters, allowing rapid filtration and eliminating the need for filter replacement, thus enhancing operational efficiency and factor enrichment.
Smart Images

Figure 2024170275000001 
Figure 2024170275000002
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing cell-free plasma or serum, and more specifically to a method for producing cell-free plasma or serum enriched in VEGF or IGF1. [Background technology]
[0002] Several companies are already offering blood processing services, including fractionation and purification of plasma from whole blood, followed by freeze-drying. Plasma contains large amounts of growth factors such as PDGF-BB, VEGF, and IGF, and this processed product is used in treatments (such as knee joint treatment in the orthopedic field and hair loss treatment in the AGA field). These services are carried out using acellular processed products that do not contain cells. Therefore, there is a demand for the production of cell-free plasma or serum that is enriched with growth factors such as VEGF and IGF1.
[0003] Patent Document 1 discloses an invention that provides a growth factor mixture that can be stored for a long period of time and a method for producing the same, which discloses a method for preparing a growth factor mixture from blood, comprising the steps of separating platelet-rich plasma from blood, removing cells from the platelet-rich plasma to obtain cell-free plasma, and freeze-drying the cell-free plasma to obtain a growth factor mixture. However, Patent Document 1 does not mention ultrasonic disruption treatment.
[0004] Patent Document 2 describes a method for preparing a particulate freeze-dried platelet lysate composition, comprising the steps of obtaining a platelet source containing platelets and a fluid carrier; lysing the platelets to form a plurality of lysates; filtering the plurality of lysates after lysis to remove cellular debris; and freeze-drying the plurality of lysates to form a particulate freeze-dried platelet lysate composition having a released concentration of available growth factors, cytokines, and chemokines, and describes that the lysing step includes using ultrasonic treatment on the platelet source. However, the examples in Patent Document 2 only suggest the abstract use of ultrasonic treatment, noting that ultrasonic treatment, filtration, etc. can also be used instead of or in addition to the freeze-thaw cycle described herein to lyse or collect platelets, and do not disclose the results of actually performing ultrasonic treatment. In addition, the examples in Patent Document 2 examine the contents of various growth factors, but do not examine the contents of VEGF and IGF1.
[0005] Patent Document 3 discloses an invention aimed at providing a serum preparation device capable of obtaining a large amount of serum capable of exhibiting high culture efficiency at one time regardless of the freshness of blood used, and discloses a serum preparation device for preparing serum from blood containing at least platelets, the serum preparation device comprising a blood reservoir for storing the blood, an ultrasonic oscillator accommodating section provided in the blood reservoir for accommodating an ultrasonic oscillator that generates ultrasonic waves, and a component accommodating section connected aseptically and airtightly to the blood reservoir for accommodating serum separated from the blood stored in the blood reservoir. However, the examples in Patent Document 3 merely quantify TGF-β1 and PDGF-BB, and do not examine the contents of VEGF and IGF1.
[0006] Patent Document 4 discloses an embodiment of a device, system, and method for producing an adjusted autologous platelet solution at a patient's bedside for simultaneous reinfusion into the patient, the device comprising: a housing; an inflow port into the housing for providing an inflow of a platelet-containing solution; a lysis / activation chamber in fluid communication with the inflow port and positioned within the housing, where one or more platelets in the platelet-containing solution flowing into the device are lysed or activated in the lysis / activation chamber, thereby creating an adjusted solution; and an outflow port from the housing in fluid communication with the lysis / activation chamber for providing the adjusted solution, which is removed through an outflow port. Patent Document 4 discloses that the device further comprises at least one acoustic transducer within the housing, the acoustic transducer being mechanically coupled to the lysis / activation chamber, and configured to pass acoustic energy through the lysis / activation chamber to cause ultrasonic lysis or activation of one or more platelets in the platelet-containing solution in the lysis / activation chamber. In the examples of Patent Document 4, the protein concentrations of TGF-β and VEGF growth factors are compared. However, the examples of Patent Document 4 do not disclose an example in which ultrasonic treatment was actually performed, and do not compare the protein concentrations of TGF-β and VEGF growth factors as examples in which ultrasonic treatment was actually performed. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] JP 2019-178116 A [Patent Document 2] Special Publication No. 2018-517771 [Patent Document 3] JP 2013-209409 A [Patent Document 4] Special Publication No. 2016-504165 Summary of the Invention [Problem to be solved by the invention]
[0008] Thus, the use of ultrasonic treatment as a method for concentrating growth factors was proposed abstractly without the backing of actual experimental results. However, according to the results of actual experiments, it was found that, as shown in the examples below, ultrasonic treatment of VEGF, among growth factors, did not concentrate VEGF but rather reduced the content of VEGF, and a similar tendency was observed for IGF1.
[0009] Since plasma components can be easily collected by centrifugation, there is little knowledge about processing them to increase the amount of growth factors, and additives such as reagents are preferably avoided as much as possible from a safety perspective. Furthermore, since the plasma fraction after centrifugation contains various protein components, clogging is often seen in the acellular processing process that involves filter filtration. These points are challenges for plasma processing services.
[0010] Therefore, an object of the present invention is to provide a method for producing cell-free plasma or serum enriched with VEGF or IGF1 with excellent operability, such as by preventing clogging during filter filtration, allowing filtration to be completed in a short time, and eliminating the need for filter replacement. [Means for solving the problem]
[0011] The present inventors have made extensive studies and have unexpectedly found that a cell-free plasma or serum enriched with VEGF or IGF1 can be produced with excellent operability by a method including a step of obtaining plasma or serum after ultrasonic disruption by ultrasonic disruption at an output of 5 W to 500 W, and a step of obtaining cell-free plasma or serum by removing cells from the obtained plasma or serum after ultrasonic disruption. In view of the fact that it has been recognized that, among growth factors, it is not possible to produce cell-free plasma or serum enriched with VEGF or IGF1 even by ultrasonic treatment, and rather that the content of these factors in cell-free plasma or serum decreases when ultrasonic treatment is performed, this finding by the present inventors is extremely unexpected.
[0012] That is, the present invention provides the following. [Aspect 1] A method for producing cell-free plasma or serum enriched with VEGF or IGF1, comprising the steps of: ultrasonically disrupting plasma or serum at an output of 5 W to 500 W to obtain post-sonication plasma or serum; and removing cells from the post-sonication plasma or serum to obtain cell-free plasma or serum. [Aspect 2] The method according to embodiment 1, wherein the output in the ultrasonic disruption treatment is 7 W to 100 W. [Aspect 3] The method according to embodiment 1, wherein the ultrasonic disruption treatment is carried out for 5 seconds to 30 minutes. [Aspect 4] The method according to embodiment 1, wherein the ultrasonic disruption treatment is carried out once or in two to six separate steps. [Aspect 5] The method according to embodiment 1, wherein the ultrasonic disruption treatment is performed by a tip or cup horn. [Aspect 6] The method according to embodiment 1, wherein obtaining cell-free plasma or serum comprises removing cells through a filter. [Aspect 7] 7. The method according to embodiment 6, wherein the filter is a membrane filter having a pore size of 0.1 μm to 1 μm. [Aspect 8] The method according to embodiment 1, wherein obtaining cell-free plasma or serum comprises removing cells by centrifugation through a filter. [Aspect 9] The method according to embodiment 8, wherein the rotation speed of the centrifugation treatment is 500 rpm to 4500 rpm. [Aspect 10] The method according to embodiment 8, wherein the centrifugation time is 1 minute to 30 minutes. [Aspect 11] The production method according to embodiment 1, wherein the plasma or serum to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is a supernatant recovered by centrifuging blood. [Aspect 12] The method according to embodiment 11, wherein the rotation speed of the centrifugation treatment is 500 to 4,000 rpm. [Aspect 13] 12. The method according to embodiment 11, wherein the centrifugation time is 1 minute to 30 minutes. [Aspect 14] 12. The method according to embodiment 11, wherein the temperature during the centrifugation treatment is 4°C to 40°C. [Aspect 15] 2. The method according to claim 1, wherein the blood from which the plasma or serum is derived to be subjected to ultrasonic disruption at an output of 5 W to 500 W is stored at 0°C to 10°C for 0 minutes to 144 hours from the time of collection from a living body until the time of treatment to obtain the plasma or serum. [Aspect 16] The method according to embodiment 1, wherein the plasma to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is obtained from blood to which an anticoagulant has been added after collection from a living body. [Aspect 17] 17. The method according to claim 16, wherein the anticoagulant is a heparin salt, citric acid or a citric acid derivative. [Aspect 18] The method according to embodiment 1, wherein the serum to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is obtained from blood to which a blood coagulant has been added after collection from a living body. [Aspect 19] The method according to embodiment 1, wherein the cell-free plasma or serum enriched in VEGF or IGF1 is a lyophilisate. [Aspect 20] 20. Cell-free plasma or serum produced by the method according to any one of aspects 1 to 19. [Aspect 21] A method for producing a plasma or serum processed product for producing cell-free plasma or serum enriched with VEGF or IGF1, the method comprising a step of subjecting the plasma or serum to ultrasonic disruption at an output of 5 W to 500 W to obtain the plasma or serum processed product. Effect of the Invention
[0013] According to a more specific embodiment of the production method of the present invention, cell-free plasma or serum enriched with VEGF or IGF1 can be produced with excellent operability, such as not causing clogging during filter filtration, being able to perform filtration in a short time, and not requiring filter replacement. This is presumably because the ultrasonic disruption treatment at an output of 5 W to 500 W eliminates the problem that the presence of protein complexes in the plasma or serum fraction after centrifugation causes clogging of the filter, complicating the subsequent treatment, and lowering the concentration of VEGF or IGF1. [Brief description of the drawings]
[0014] [Figure 1] FIG. 1 is a graph showing the results of ELISA analysis of VEGF concentrations in a sample treated with ultrasonic disruption at 0 W (untreated) (condition 1), a sample treated with ultrasonic disruption three times for 10 seconds at 10 W (condition 4), and a sample treated with ultrasonic disruption three times for 10 seconds at 2 W (condition 5). [Diagram 2] FIG. 2 is a graph showing the results of ELISA analysis of IGF1 concentration in a sample treated with ultrasonic disruption at 0 W (untreated) (condition 1), a sample treated with ultrasonic disruption three times for 10 seconds at 10 W (condition 4), and a sample treated with ultrasonic disruption three times for 10 seconds at 2 W (condition 5). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] The present invention provides a method for producing cell-free plasma or serum enriched with VEGF or IGF1, comprising the steps of: ultrasonically disrupting plasma or serum at an output of 5 W to 500 W to obtain post-sonication plasma or serum; and removing cells from the post-sonication plasma or serum obtained to obtain cell-free plasma or serum.
[0016] The output in the ultrasonic disruption treatment is preferably 5W to 500W, preferably 7W to 500W, preferably 10W to 500W, more preferably 5W to 400W, more preferably 7W to 400W, more preferably 10W to 400W, even more preferably 5W to 300W, even more preferably 7W to 300W, even more preferably 10W to 300W, even more preferably 5W to 200W, even more preferably 7W to 200W, even more preferably 10W to 200W, even more preferably 5W to 100W, even more preferably 7W to 100W, and even more preferably 10W to 100W.
[0017] The ultrasonic disruption time is preferably 1 second to 45 minutes, more preferably 1 second to 30 minutes, more preferably 5 seconds to 30 minutes, even more preferably 10 seconds to 30 minutes, even more preferably 1 second to 10 minutes, even more preferably 5 seconds to 10 minutes, even more preferably 10 seconds to 10 minutes, even more preferably 1 second to 5 minutes, even more preferably 5 seconds to 5 minutes, even more preferably 10 seconds to 5 minutes. The ultrasonic disruption time may be, for example, 1 second to 1 minute, 5 seconds to 1 minute, 10 seconds to 1 minute, 1 second to 40 seconds, 5 seconds to 40 seconds, or 10 seconds to 40 seconds. In addition, when the ultrasonic disruption is performed in multiple steps, the ultrasonic disruption time refers to the total time of the ultrasonic disruption performed multiple times.
[0018] The ultrasonic disruption treatment may be carried out once or in separate steps, and is preferably carried out 2 to 10 times, more preferably 2 to 8 times, even more preferably 2 to 6 times, and even more preferably 2 to 4 times.
[0019] The ultrasonic disruption treatment is not limited, and any ultrasonic disruption treatment can be used, including known ultrasonic disruption treatments, but is preferably a tip type (e.g., Tommy Seiko, UD-100) or a cup horn type (e.g., Tommy Seiko, UD-211). The tip type includes, for example, an ultrasonic generator (a long and thin rod) that is directly inserted into the specimen for treatment. Therefore, treatment can be efficiently performed at a low wattage such as 1W to 50W. The output in the tip type ultrasonic disruption treatment is preferably 5W to 100W, preferably 7W to 100W, more preferably 5W to 90W, more preferably 7W to 90W, even more preferably 5W to 70W, even more preferably 7W to 70W, even more preferably 5W to 50W, even more preferably 7W to 50W, even more preferably 5W to 30W, and even more preferably 7W to 30W. An example of the cup horn type is one in which the entire water bath is ultrasonically vibrated to process the tube containing the specimen immersed therein beyond the tube wall. Therefore, a high output of 100W to 500W or the like is required. The output in the ultrasonic disruption treatment by the cup horn type is preferably 10W to 500W, more preferably 20W to 400W, even more preferably 30W to 300W, even more preferably 40W to 250W, and even more preferably 50W to 200W. The ultrasonic disruption treatment is carried out, for example, under sterilization or non-sterilization.
[0020] Examples of the process for removing cells from plasma or serum after ultrasonic disruption to obtain cell-free plasma or serum include a process for performing a heat treatment, a process for performing an acid treatment, and a process for removing cells using a filter. Among these, the process for removing cells using a filter is preferred because it has a low risk of causing denaturation of growth factors. Here, the filter is not limited as long as it can remove blood cells, but since the minimum size of blood cells is about 2 μm, which is the same as platelets, the filter can be preferably a membrane filter with a pore size of 1 μm or less, more preferably a pore size of 0.7 μm or less, and even more preferably a pore size of 0.5 μm or less. There is no limit to the lower limit of the pore size of the membrane filter, but if it is too small, there is a high risk of clogging. Therefore, the pore size is preferably 0.1 μm or more, and more preferably 0.2 μm or more. Among the membrane filters that are usually available on the market, there are membrane filters with a pore size of about 0.2 μm and membrane filters with a pore size of about 0.45 μm that satisfy this range, and either of these can be used in the present invention. An example of a filter is Millipore's Millex GV (SLGVR33RS), which is attached to a syringe and allows filtering by hand.
[0021] Furthermore, the step of removing cells from the plasma or serum after ultrasonic disruption to obtain cell-free plasma or serum preferably includes a step of removing cells by centrifugation through a filter. Examples of the filter include the same filters as described above. The rotation speed of the centrifugation is preferably 500 rpm to 4500 rpm, more preferably 750 rpm to 4000 rpm, even more preferably 1000 rpm to 3000 rpm, and even more preferably 1500 rpm to 2000 rpm. The time for the centrifugation is preferably 1 to 30 minutes, more preferably 3 to 20 minutes, even more preferably 4 to 15 minutes, and even more preferably 5 to 10 minutes.
[0022] In the production method of the present invention, the plasma or serum to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is preferably a supernatant recovered by centrifuging blood. Here, the rotation speed of the centrifugation treatment is preferably 500 to 4000 rpm, more preferably 1000 to 4000 rpm, even more preferably 1000 to 2000 rpm, and even more preferably 1000 to 1500 rpm. The time of the centrifugation treatment is preferably 1 to 30 minutes, more preferably 5 to 30 minutes, and even more preferably 5 to 15 minutes. The temperature during the centrifugation treatment is preferably 4°C to 40°C, more preferably 4°C to 30°C, and even more preferably 4°C to 25°C. The temperature during the centrifugation treatment may be 10°C to 40°C, 15°C to 30°C, or 20°C to 25°C.
[0023] The blood from which the plasma or serum to be ultrasonically disrupted at an output of 5W to 500W, such as the blood to be centrifuged, is derived is preferably stored for 0 minutes from collection from a living body to processing to obtain plasma or serum, such as centrifugation, but may be stored for 1 minute to 144 hours, more preferably 2 minutes to 120 hours, even more preferably 3 minutes to 96 hours, and even more preferably 4 minutes to 72 hours. The temperature during storage is, for example, 0°C to 10°C, more preferably 2°C to 8°C, even more preferably 4°C to 6°C, and even more preferably 4°C to 5°C. The production method of the present invention does not undergo significant changes even during storage, and can meet the need for transporting the blood sample. Here, the blood from which the plasma or serum to be ultrasonically disrupted at an output of 5W to 500W is derived is preferably blood to which a blood coagulation inhibitor or blood coagulant has been added. In this case, the start of the storage time may be the time when the blood coagulation inhibitor or blood coagulant is added.
[0024] In the production method of the present invention, the plasma to be ultrasonically disrupted at an output of 5 W to 500 W is preferably obtained from blood to which an anticoagulant has been added after collection from a living body. Examples of the anticoagulant include heparin salts such as sodium heparin, citric acid such as citric acid hydrate, citrate salts such as sodium citrate and sodium citrate hydrate, citric acid derivatives such as dextrose citrate, and EDTA salts such as EDTA-2Na and EDTA-2K.
[0025] In the production method of the present invention, the serum to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W may be obtained by, for example, blood clot formation without using a blood coagulant, or may be obtained from blood to which a blood coagulant has been added after collection from a living body. Examples of blood coagulants include thrombin and fibrinogen.
[0026] The blood to which the anticoagulant or blood coagulant is added may be stored after collection from a living body and before the anticoagulant or blood coagulant is added. The storage time is preferably 0 minutes to 72 hours, more preferably 0 minutes to 48 hours, even more preferably 0 minutes to 24 hours, and even more preferably 0 minutes to 1 hour. The temperature during storage is preferably 0°C to 10°C, more preferably 1°C to 8°C, even more preferably 2°C to 6°C, and even more preferably 3°C to 5°C. The production method of the present invention does not undergo significant changes even during such storage, and can meet the need for transporting blood as a sample.
[0027] The cell-free plasma or serum produced by the production method of the present invention may contain excipients, additives, buffers, salts for adjusting isotonicity, antioxidants, preservatives, drug stabilizers, etc. Examples of excipients include, but are not limited to, water, purified water, physiological saline, alcohol, glycerin, lactose, starch, glucose, dextrin, sucrose, precipitated silica, honey, rice starch, tragacanth, etc. Furthermore, the cell-free plasma or serum produced by the production method of the present invention may be a lyophilized product.
[0028] The cell-free plasma or serum produced by the production method of the present invention may be any plasma or serum that has been subjected to a step of removing cells, and therefore the mere detection of cells does not negate the fact that the plasma or serum is cell-free. However, the cell-free plasma or serum produced by the production method of the present invention is preferably one in which no cells are detectable, and more preferably one in which cells have been completely removed. EXAMPLES
[0029] Example 1: Approximately 40 mL of whole blood was collected from one adult male volunteer, and the collected whole blood was placed in a heparin tube (BML Co., Ltd.), which is a blood anticoagulant-containing tube, mixed by inversion, and then stored. The heparin tube contains heparin sodium, which is a blood coagulation inhibitor, and ACD liquid (ingredients: sodium citrate hydrate, citric acid hydrate, glucose). These were refrigerated overnight (approximately 16 hours) at 4°C in a thermostatic bath. After refrigerated storage, the samples were centrifuged (1300 rpm, 10 minutes, 24°C) to collect the supernatant plasma (approximately 20 mL). Using a non-sterile ultrasonic generator (ultrasonic homogenizer) (Tommy Seiko, Handy Sonic, UR-20P), the plasma was subjected to ultrasonic disruption treatment at output of 0W, 2W, or 10W, three times for 10 seconds each, to obtain three types of samples. After ultrasonic disruption, the blood was transferred to a syringe and filtered through a membrane filter with a pore size of 0.22 μm to remove cellular components. This filtering separated the blood cells remaining on the filter from the liquid that passed through the filter (cell-free plasma). Approximately 18 mL of cell-free plasma was dispensed into 9 vials, 2 mL each, and stored frozen at -80°C to obtain samples.
[0030] The concentrations of growth factors VEGF and IGF1 were analyzed for the obtained samples by ELISA. The results for VEGF are shown in Figure 1, and the results for IGF1 are shown in Figure 2. In Figures 1 and 2, condition 1 is the result for a sample that was subjected to ultrasonic disruption at 0 W (untreated). Condition 4 is the result for a sample that was subjected to ultrasonic disruption three times for 10 seconds at 10 W. Condition 5 is the result for a sample that was subjected to ultrasonic disruption three times for 10 seconds at 2 W.
[0031] As shown in Figures 1 and 2, when ultrasonic disruption is performed at an output of 2 W, for example, performing ultrasonic disruption treatment three times for 10 seconds at 2 W, the concentration of the cytokine VEGF does not increase, but rather decreases. However, quite unexpectedly, when ultrasonic disruption is performed at an output of 10 W, for example, performing ultrasonic disruption treatment three times for 10 seconds at 10 W, the concentration of the cytokine VEGF increases, and a similar tendency was observed for the concentration of the cytokine IGF1.
[0032] In addition, ultrasonic disruption enabled smooth filtration using 0.22 μm filters, etc. That is, filtration took 15 seconds at 0 W, and sometimes the filter had to be replaced due to clogging, but filtration took 5 seconds at 2 W and 1 second at 5 W under the same conditions, and there was no need to replace the filter, significantly reducing the time required for this process.
Claims
1. A method for producing cell-free plasma or serum enriched with VEGF or IGF1, comprising the steps of: ultrasonically disrupting plasma or serum at an output of 5 W to 500 W to obtain sonicated plasma or serum; and removing cells from the sonicated plasma or serum to obtain cell-free plasma or serum.
2. The method according to claim 1, wherein the output in the ultrasonic disruption treatment is 7 W to 100 W.
3. The method according to claim 1, wherein the ultrasonic disruption treatment time is from 5 seconds to 30 minutes.
4. The method according to claim 1, wherein the ultrasonic disruption treatment is carried out once or in two to six separate steps.
5. The method according to claim 1, wherein the ultrasonic disruption treatment is performed by a tip type or a cup horn type.
6. The method according to claim 1 , wherein the step of obtaining cell-free plasma or serum comprises removing cells using a filter.
7. The method according to claim 6, wherein the filter is a membrane filter having a pore size of 0.1 μm to 1 μm.
8. The method according to claim 1 , wherein the step of obtaining cell-free plasma or serum comprises removing cells by centrifugation through a filter.
9. The method according to claim 8, wherein the rotation speed of the centrifugation treatment is 500 rpm to 4500 rpm.
10. The method according to claim 8, wherein the centrifugation time is from 1 minute to 30 minutes.
11. The method according to claim 1, wherein the plasma or serum to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is a supernatant recovered by centrifuging blood.
12. The method according to claim 11, wherein the rotation speed of the centrifugation treatment is 500 to 4000 rpm.
13. The method according to claim 11, wherein the centrifugation time is from 1 minute to 30 minutes.
14. The method according to claim 11, wherein the temperature during the centrifugation treatment is 4°C to 40°C.
15. The method according to claim 1, wherein the blood from which the plasma or serum is derived to be subjected to ultrasonic disruption at an output of 5 W to 500 W is stored at 0° C. to 10° C. for 0 minutes to 144 hours from collection from a living body to treatment for obtaining the plasma or serum.
16. The method according to claim 1, wherein the plasma to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is obtained from blood to which an anticoagulant has been added after collection from a living body.
17. 17. The method of claim 16, wherein the anticoagulant is a heparin salt, citric acid or a citric acid derivative.
18. The method according to claim 1, wherein the serum to be subjected to ultrasonic disruption treatment at an output of 5 W to 500 W is obtained from blood to which a blood coagulant has been added after collection from a living body.
19. The method according to claim 1, wherein the cell-free plasma or serum enriched with VEGF or IGF1 is a lyophilized product.
20. 20. Cell-free plasma or serum produced by the method according to any one of claims 1 to 19.
21. A method for producing a plasma or serum processed product for producing cell-free plasma or serum enriched with VEGF or IGF1, the method comprising a step of subjecting the plasma or serum to ultrasonic disruption at an output of 5 W to 500 W to obtain the plasma or serum processed product.
Citation Information
Patent Citations
Enrichment method of platelet cell factor concentrates
CN107446036A
Preparation method of poultry plasma protein
CN108813090A
Preparation method of blood wall-breaking growth factor and application thereof
CN110028571A
Serum preparation apparatus
JP2013209409A
Method for producing platelet concentrated pharmaceutical preparation
JP2017171597A
